{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:40:22Z","timestamp":1722040822014},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.farma.2024.02.003","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T15:34:03Z","timestamp":1709912043000},"page":"176-179","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of retreatment with monoclonal antibodies in chronic\/episodic migraine: Real world data"],"prefix":"10.1016","volume":"48","author":[{"given":"Patricia","family":"Garc\u00eda-Lloret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Galv\u00e1n-Banqueri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda de las Aguas","family":"Robustillo-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Fern\u00e1ndez-Recio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2024.02.003_bb0005","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"},{"issue":"1","key":"10.1016\/j.farma.2024.02.003_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders, 3rd edition","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","journal-title":"Cephalalgia"},{"issue":"3","key":"10.1016\/j.farma.2024.02.003_bb0015","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/WCO.0000000000000438","article-title":"Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies","volume":"30","author":"Mitsikostas","year":"2017","journal-title":"Curr Opin Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.farma.2024.02.003_bb0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/head.13302","article-title":"A review of monoclonal antibody therapies and other preventative treatments in migraine","volume":"58","author":"Reuter","year":"2018","journal-title":"Headache."},{"key":"10.1016\/j.farma.2024.02.003_bb0025","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"},{"issue":"1","key":"10.1016\/j.farma.2024.02.003_bb0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J Headache Pain"},{"issue":"11\u201312","key":"10.1016\/j.farma.2024.02.003_bb0035","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/03331024211014616","article-title":"Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study","volume":"41","author":"Gantenbein","year":"2021","journal-title":"Cephalalgia."},{"issue":"1","key":"10.1016\/j.farma.2024.02.003_bb0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s10194-019-1018-8","article-title":"Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination","volume":"20","author":"Raffaelli","year":"2019","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1016\/j.farma.2024.02.003_bb0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/pharmaceutics15010293","article-title":"Change of CGRP plasma concentrations in migraine after discontinuation of CGRP-(receptor) monoclonal antibodies","volume":"15","author":"Raffaelli","year":"2023","journal-title":"Pharmaceutics."},{"issue":"1","key":"10.1016\/j.farma.2024.02.003_bb0050","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s10194-022-01417-9","article-title":"Resumption of migraine preventive treatment with CGRP(\u2212receptor) antibodies after a 3-month drug holiday: a real-world experience","volume":"23","author":"Raffaelli","year":"2022","journal-title":"J Headache Pain"},{"issue":"8","key":"10.1016\/j.farma.2024.02.003_bb0055","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.medcli.2022.09.023","article-title":"Effectiveness of anti-CGRP monoclonal antibodies in the preventive treatment of migraine: A prospective study of 63 patients Efectividad de anticuerpos monoclonales anti-PRGC en el tratamiento preventivo de la migra\u00f1a: estudio prospectivo de 63 pacientes","volume":"160","author":"Castrillo","year":"2023","journal-title":"Med Clin (Barc)"},{"issue":"2","key":"10.1016\/j.farma.2024.02.003_bb0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000527674","article-title":"Migraine disability and severity improvement during long-term treatment with erenumab","volume":"86","author":"Bolchini","year":"2023","journal-title":"Eur Neurol"},{"issue":"11","key":"10.1016\/j.farma.2024.02.003_bb0065","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1007\/s00415-023-11872-2","article-title":"Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study","volume":"270","author":"Vernieri","year":"2023","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.farma.2024.02.003_bb0070","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1007\/s10072-022-05870-x","article-title":"Chronic migraine evolution after 3\u202fmonths from erenumab suspension: real-world-evidence-life data","volume":"43","author":"Guerzoni","year":"2022","journal-title":"Neurol Sci"},{"issue":"5","key":"10.1016\/j.farma.2024.02.003_bb0075","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/ene.15260","article-title":"Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine","volume":"29","author":"Iannone","year":"2022","journal-title":"Eur J Neurol"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324000230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324000230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:14:29Z","timestamp":1722039269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634324000230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1130634324000230"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2024.02.003","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of retreatment with monoclonal antibodies in chronic\/episodic migraine: Real world data","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}